Telix Reports US$230M Q1 Revenue as Four Cancer Therapy Trials Reach Milestones

Telix delivers US$230 million Q1 revenue as therapeutics pipeline hits key milestones

Telix Pharmaceuticals (ASX: TLX) has reported Q1 2026 revenue of US$230 million, representing 11% quarter-on-quarter growth and 24% year-on-year growth. The radiopharmaceutical company reaffirmed its FY 2026 revenue guidance of US$950 million to US$970 million, signalling management confidence in the business trajectory.

Precision Medicine revenue reached US$186 million in Q1 2026, up 16% quarter-on-quarter, driven by strong performance across both Illuccix and Gozellix imaging products. U.S. dose volumes increased 5% quarter-on-quarter despite extreme weather disruptions, demonstrating the resilience of the pharmacy distribution model. Telix Manufacturing Solutions third-party revenue contributed US$44 million, up 29% year-on-year.

The quarter’s performance reflects dual-track progress, with commercial growth funding advancement across the therapeutics pipeline. Four clinical programmes achieved key milestones, positioning multiple potential regulatory catalysts through 2026 and beyond.

What is radiopharmaceutical theranostics and why it matters for cancer treatment

Radiopharmaceutical theranostics refers to the use of the same targeting molecule for both diagnosis (imaging) and treatment (therapy). This approach allows clinicians to identify patients who express specific biomarkers through imaging, then treat those same patients with a therapeutic version of the same targeting agent.

In prostate cancer, PSMA (prostate-specific membrane antigen) serves as the biomarker target. Telix’s imaging products Illuccix and Gozellix enable physicians to visualise PSMA expression using PET/CT scans. Once a patient is confirmed PSMA-positive through imaging, they become candidates for PSMA-targeted therapies like the company’s TLX591-Tx candidate currently in Phase 3 trials.

This theranostics model creates a strategic pathway for Telix. The established imaging products generate commercial revenue whilst building physician familiarity with PSMA targeting. When therapeutic products receive regulatory approval, the existing imaging infrastructure and clinical relationships provide a foundation for rapid adoption. For investors, this represents a de-risked commercialisation pathway compared to launching therapeutic products into markets without established diagnostic infrastructure.

Commercial performance accelerates across both imaging products

U.S. dose volumes and market share gains

Precision Medicine revenue of US$186 million in Q1 2026 marked 16% quarter-on-quarter growth and 23% year-on-year growth. The two-product PSMA imaging strategy, combining Illuccix and Gozellix, contributed to market share gains underpinned by disciplined pricing and service delivery.

U.S. dose volumes grew 5% quarter-on-quarter despite severe weather disruptions across North America. The pharmacy distribution model proved advantageous during these conditions, maintaining supply continuity when alternative distribution channels faced challenges. Telix Manufacturing Solutions third-party revenue reached US$44 million, reflecting 29% year-on-year growth.

Global expansion creating platform for future launches

Illuccix is now launched in 21 countries globally, including 16 European countries. This expanding international footprint enhances access to PSMA-PET/CT imaging whilst establishing scalable commercial and operational infrastructure to support future therapeutic product launches.

The NMPA (National Medical Products Administration) in China accepted the NDA (New Drug Application) for TLX591-Px (branded as Illuccix outside China) in January 2026. The broad proposed label is under review, positioning potential market access in a significant geographic region.

Geographic diversification reduces single-market revenue concentration risk whilst creating distribution channels and clinical relationships ahead of therapeutic product approvals. The commercial infrastructure built through imaging product sales can be leveraged for therapy launches, reducing commercialisation costs and accelerating adoption.

Therapeutics pipeline advances across four clinical programmes

ProstACT Global Phase 3 trial meets Part 1 objectives

Part 1 of the ProstACT Global Phase 3 trial for TLX591-Tx achieved its safety and dosimetry objectives with no new safety signals observed. The lead-in phase demonstrated an acceptable safety and tolerability profile, with no adverse drug-drug interactions when TLX591-Tx was combined with standard of care therapies.

The data supports the feasibility of integrating TLX591-Tx with ARPIs (androgen receptor pathway inhibitors) such as enzalutamide or abiraterone, and with docetaxel. This combination capability is clinically significant, as it positions TLX591-Tx to integrate into existing treatment protocols rather than requiring treatment line displacement.

Part 2 enrollment is open in Australia, New Zealand and Canada. Site activation is underway in China, Singapore, South Korea, Türkiye, the United Kingdom and Japan, where regulatory approvals have been granted. Telix has commenced engagement with the FDA to present Part 1 data and determine eligibility for U.S. patients to participate in the randomised treatment expansion phase.

Additional pipeline momentum

Four additional programmes achieved clinical milestones during Q1 2026:

• TLX250-Tx: First clinical site opened for LUTEON pivotal trial in advanced clear cell renal cell carcinoma (ccRCC). The trial is recruiting patients for Part 1 of the monotherapy study, with initial recruitment focused ex-U.S.

• TLX101-Tx: First patient enrolled in IPAX-BrIGHT, an international pivotal trial in recurrent glioblastoma. Enrollment is open in Australia, Austria and the Netherlands, with regulatory approval granted to commence in Belgium.

• TLX090-Tx: SOLACE Phase 1 study expanded to additional U.S. sites to accelerate recruitment. The study is evaluating the candidate for treating pain in patients with osteoblastic bone metastases from prostate and breast cancers.

• TLX597-Tx: Interim data from OPTIMAL-PSMA, an investigator-led randomised dose intensification study in metastatic castration-resistant prostate cancer (mCRPC), will be presented at the International Prostate Cancer Symposium in April 2026. Early clinical data suggests favourable biodistribution with limited uptake in healthy organs relative to available lutetium-177 PSMA therapies.

Multiple active clinical programmes across different cancer types reduces binary risk associated with single-programme dependency. Each programme represents a distinct commercial opportunity with separate regulatory pathways and market dynamics.

Regulatory submissions position near-term catalysts

Regulatory activity across three product candidates creates multiple potential approval catalysts through 2026:

1. TLX101-Px (brain imaging): NDA resubmitted to FDA in March 2026 with additional clinical data and analysis as agreed with the agency. MAA filed in Europe in February 2026, covering commercially significant markets.

2. TLX250-Px (kidney cancer imaging): BLA resubmission targeted for H1 2026 following two successful FDA Type A meetings. Telix has aligned on outstanding issues, including demonstration of drug product comparability between clinical trial material and scale-up commercial production.

3. TLX591-Px (Illuccix): NDA accepted by NMPA in China. The broad proposed label is under review by the Centre for Drug Evaluation.

Multiple regulatory decisions expected in 2026 create potential value inflection points independent of commercial revenue performance. Successful approvals expand the approved product portfolio, diversify revenue streams and validate the clinical and regulatory execution capabilities.

Management perspective and governance update

Dr. Christian Behrenbruch, Managing Director and Group CEO

“Growth accelerated across our Precision Medicine business in the first quarter, with U.S. dose volumes increasing 5% quarter-over-quarter. This performance reflects the growing uptake of Gozellix alongside Illuccix, contributing to market share gains underpinned by disciplined sales execution and pricing, and high-quality service delivery despite extreme North American weather conditions, an advantage of the pharmacy distribution model. With our two-product PSMA imaging strategy, differentiated clinical positioning and expanding commercial presence globally, we are seeing a solid foundation for continued growth through 2026. Importantly, we are delivering on our strategic priorities to advance our high-value clinical programs, demonstrated by the momentum in our therapeutics pipeline this quarter.”

The company announced the appointment of David Gill as Non-Executive Director effective 11 May 2026, as part of Board renewal. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson, who will remain on the Board as Non-Executive Director.

The Board identified Mr. Gill’s extensive experience in U.S. public company governance, financial oversight and senior leadership across commercial and clinical-stage biopharmaceutical companies as enhancing Board capability. Board renewal with U.S.-focused expertise signals continued commitment to the dual-listing strategy and institutional investor engagement.

FY 2026 outlook and investment considerations

Telix reaffirmed FY 2026 revenue guidance of US$950 million to US$970 million. The guidance reflects revenue from product sales in jurisdictions with marketing authorisation and a full year of revenue contribution from RLS Radiopharmacies.

Research and development expenditure guidance of US$200 million to US$240 million was also reaffirmed, subject to achieving ongoing global commercial milestones. The R&D investment level reflects confidence in pipeline value creation potential whilst commercial revenue growth provides funding capacity.

Near-term catalysts for investors to monitor include:

• Part 2 ProstACT Global enrollment expansion, pending U.S. patient eligibility determination
• TLX101-Px FDA NDA review outcome following resubmission
• TLX250-Px BLA resubmission targeted for H1 2026
• TLX597-Tx interim data presentation at International Prostate Cancer Symposium in April 2026

The reaffirmed guidance provides revenue visibility through calendar 2026, whilst R&D investment supports multiple clinical programmes advancing towards pivotal data readouts. The business model demonstrates commercial growth funding pipeline advancement, reducing dependency on capital markets for therapeutic development funding.

Want the Next Biotech Breakthrough in Your Inbox?

Join 20,000+ investors receiving FREE ASX healthcare and biotech alerts within minutes of release, complete with expert analysis. Get breaking news the moment it hits the market by clicking the “Free Alerts” button at StockWire X and stay ahead on sector-moving announcements.